Trial Profile
Phase I Study of MOC31-PE in Antigen Positive Carcinomas.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2023
Price :
$35
*
At a glance
- Drugs Monoclonal antibody moc 31 PE conjugate (Primary)
- Indications Cancer
- Focus Adverse reactions
- 10 Nov 2015 Results published in the British Journal of Cancer
- 03 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 May 2012 Actual end date (February 2012) added as reported by ClinicalTrials.gov.